Skip to main content
Commentary Health Impact Investment

Why we invest in – Varian; using innovation to fight cancer

Image for Varian article
  • Varian is a global leader in the field of radiation therapy with around 50% market share.
  • The radiation therapy market is a growing market, driven by an increasing cancer rate globally and increasing adoption of radiation therapy in emerging markets.
  • Varian is a very innovative company, driving business growth through successful product launches and gaining market share.
  • It is well positioned to expand into adjacent fast-growing markets to sustain its future growth through its R&D effort and acquisitions.

1 in 2 people will be diagnosed with cancer in their lifetime and nearly half of cancer patients have radiation therapy at some point during their cancer treatment. Varian is a global market leader in the field of radiation therapy, developing devices including linear accelerators and software for treating cancer. Its vision is a world without fear of cancer. Varian aims to increase the number of patients worldwide cared for with its technology from 3 million today to 6 million by 2022.

With the advance of medical technologies and improving diets, global average life expectancy has increased. Sadly, as we live longer, cancer risk also increases. This backdrop creates a growing demand for radiation therapy as it is an effective and relatively affordable treatment option for cancer patients. This market is estimated to grow at 4% annually to $6.3 billion in 2022. The market for radiation therapy equipment is consolidated, dominated by two major players Varian and Elekta. They compete on innovation and technology, which results in better clinical outcomes and lower side-effects for patients.

Varian’s strategy is to transform itself from a global leader in radiation therapy to be a front-runner in multi-disciplinary integrated cancer care solutions. This approach helps it strengthen its leadership in radiation therapy, expand its addressable market and extend its global footprint. One of its plans is to expand into the adjacent markets of Care Coordination and Interventional Oncology. Care Coordination is a fast growing market due to the increasing complexity of cancer care. The market is expected to grow 20% annually to $6 billion in 2022. Varian introduced its 360 Oncology care management platform in 2016, bringing together radiation, medical and surgical oncology, social services and primary care physicians to facilitate true coordinated care. This platform enables doctors to provide the highest quality, evidence-based care plan and best clinical outcome possible. Interventional Oncology is another fast growing adjacent market, estimated to grow at 8% annually to 2022. Varian launched Rapidsphere in 2018, a cancer imaging software for the interventional oncology market. The software can aggregate unstructured treatment and imaging data from diverse systems to show a comprehensive view of a patient’s diagnostic imaging and treatment history.

To maintain its competitiveness, Varian is committed to innovation and generally spends 8% of its sales on research and development. There are numerous examples which demonstrate its leadership in innovation. Varian introduced a new cancer treatment device Halycon in 2017 to target emerging markets. Halycon aims to reduce the total cost of ownership and provide faster treatment times to meet the high demand for high-throughput cancer centres in the emerging markets. It also launched a new proton therapy system ProBeam 360 in 2018 with 30% smaller footprint and faster treatment times.

Varian is a pioneer in radiation therapy and we believe it will play an even bigger role in cancer care solutions in the future.

 

We invest in this stock for the following reasons:

  • Secular market growth: Radiation therapy is a growing market driven by the growing prevalence of cancer and the increasing adoption of radiation therapy in emerging markets.
  • Dominant market leader: Varian has around 50% market share in radiation therapy and is increasing its share.
  • Innovative excellence: Varian is fully committed to innovation. Its technological leadership is evidenced by the successful launch of Halycon, which was selected as one of 2018’s most exceptional innovations in science and technology.
  • Expanding addressable market: Varian has successfully expanded into faster growing adjacent markets through internal development and acquisition.

Foresight Group LLP completed an acquisition of the trade and assets of WHEB Asset Management LLP (WHEB). By way of Novation, Foresight Group LLP now acts as investment manager. Foresight Group LLP uses the trading names WHEB and WHEB Asset Management.

Foresight Group LLP and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 198020 and has its registered office at The Shard, 32 London Bridge Street, London, SE1 9SG. FundRock Partners Limited (formerly Fund Partners Limited) remains the Authorised Corporate Director of the Funds and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 469278 and has its registered office at Hamilton Centre, Rodney Way, Chelmsford, England, CM1 3BY.

Important Notices:

The price of shares (“Shares”) in FP WHEB Sustainability Impact Fund, WHEB Sustainable Impact Fund or WHEB Environmental Impact Fund may increase or decrease and you may not get back the amount originally invested, for reasons including adverse market and foreign exchange rate movements. Past performance does not predict future returns. Any performance shown does not take account of any commissions and costs charged when subscribing to and redeeming shares. The Fund invests in equities and is exposed to price fluctuations in the equity markets and focuses on investments in mid-sized companies in certain sectors so its performance may not correlate closely with the MSCI World Index (the benchmark). For full risks, please see fund prospectus on www.whebgroup.com. This information is issued by Foresight Group LLP. We have exercised reasonable care in preparing this information including using reliable sources. However, we make no representation or warranty relating to its accuracy, reliability or completeness or whether any future event may or may not occur. The information (including the MSCI information) is intended for information purposes only and does not constitute or form part of any offer or invitation to buy or sell any security. Any opinions constitute our judgment as of the date published and are subject to change without notice. We do not offer legal, tax, financial or investment advice. The information should not be relied upon to make an investment decision. Any such investment decision should be made only on the basis of the Fund scheme documents and appropriate professional advice.

WHEB Environmental Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The Fund is registered for distribution to professional investors in the United Kingdom. It is not available to investors domiciled in the United States.

FP WHEB Sustainability Impact Fund

FundRock Partners Limited is the Authorised Corporate Director of the Fund and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 469278 and has its registered office at 6th Floor Bastion House, 140 London Wall, London, EC2Y 5DN. The state of the origin of the Fund is England and Wales.

WHEB Sustainable Impact Fund

The Manager of the Fund is FundRock Management Company S.A., authorised and regulated by the Luxembourg regulator to act as UCITS management company and has its registered office at 33, rue de Gasperich, L-5826 Hesperange, Grand-Duchy of Luxembourg. The state of the origin of the Fund is Ireland. The Fund is registered for distribution to professional investors in Austria, France, Germany, Italy, Luxembourg, Norway, Singapore, Sweden and the United Kingdom, and is registered for offering to retail investors in Switzerland, Denmark and the Netherlands. The Fund is also available for professional investors in Belgium and Hong Kong. It is not available to investors domiciled in the United States.

For FP WHEB Sustainability Impact Fund and WHEB Sustainable Impact Fund, the Representative in Switzerland is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, 8024 Zurich.  The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the representative in Switzerland.

The MSCI information may be used for your internal use, may not be reproduced or re-dissseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).

Join our mailing list

Sign up below for regular email updates about our funds, our impact, our events.
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
WHEB is now a part of Foresight Group.
Authorised and regulated by the Financial Conduct Authority
Copyright 2025© WHEB. All rights reserved Made by Thursday